Table 3.
Relationship between premorbid antithrombotic therapy, pre-morbid CHADS2 score and age of onset of incident AF-related ischaemic stroke or systemic embolism
| Age group | Warfarin | No anti-thrombotics | Mono-antiplatelet | Dual-antiplatelet |
|---|---|---|---|---|
| n, (%) | n, (%) | n, (%) | n, (%) | |
| <60 | 5 (55.6) | 1 (11.1) | 3 (33.3) | 0 |
| 60-69 | 8 (28.6) | 7 (25.0) | 13 (46.4) | 0 |
| 70-79 | 24 (26.4) | 19 (20.9) | 44 (48.4) | 4 (4.4) |
| 80-89 | 19 (12.9) | 42 (28.6) | 83 (56.5) | 3 (2.0) |
| ≥90 | 0 | 17 (27.9) | 39 (63.9) | 5 (8.2) |
| Total | 56 (16.7) | 86 (25.6) | 182 (54.2) | 12 (3.6) |
| CHADS2 <2 | ||||
| <60 | 1 (20.0) | 1 (20.0) | 3 (60.0) | 0 |
| 60-69 | 6 (33.3) | 4 (22.2) | 8 (44.4) | 0 |
| 70-79 | 6 (19.4) | 6 (19.4) | 19 (61.3) | 0 |
| 80-89 | 3 (17.6) | 8 (47.1) | 5 (29.4) | 1 (5.9) |
| ≥90 | 0 | 3 (37.5) | 4 (50.0) | 1 (12.5) |
| Total | 16 (20.3) | 22 (27.8) | 39 (49.4) | 2 (2.5) |
| CHADS2 ≥2 | ||||
| <60 | 4 (100) | 0 | 0 | 0 |
| 60-69 | 2 (20.0) | 3 (30.0) | 5 (50.0) | 0 |
| 70-79 | 18 (30.0) | 13 (21.7) | 25 (41.7) | 4 (6.7) |
| 80-89 | 16 (12.3) | 34 (26.2) | 78 (60.0) | 2 (1.5) |
| ≥90 | 0 | 14 (26.4) | 35 (66.0) | 4 (7.5) |
| Total | 40 (15.6) | 64 (24.9) | 143 (55.6) | 10 (3.9) |